; (ii) the role of the private sector in such activities; (iii) how the authority for mosquito control impacts such activities; and (iv) the funding sources for such infrastructure and programs, including Federal, State, and local funding sources; (B) how mosquito-borne and other vector-borne disease surveillance and control is integrated into Federal, State, and local preparedness plans and actions, including how zoonotic surveillance is integrated into infectious disease surveillance to support real-time situational surveillance and awareness; (C) Federal, State, and local laboratory capacity for emerging vector-borne diseases, including mosquito-borne and other zoonotic diseases; and (D) any regulatory challenges for developing and utilizing vector-control technologies and platforms as part of mosquito control strategies. (2) Consultations In conducting the study under paragraph (1), the Comptroller General of the United States shall consult with— (A) State and local public health officials involved in mosquito and other vector-borne disease surveillance and control efforts; (B) researchers and manufacturers of mosquito control products; (C) stakeholders involved in mosquito abatement activities; (D) infectious disease experts; and (E) entomologists involved in mosquito-borne disease surveillance and control efforts. (3) Report Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing— (A) the results of the study conducted under paragraph (1)